Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

6.3K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
6.3K
Induced Pluripotent Stem Cells01:13

Induced Pluripotent Stem Cells

28.7K
Stem cells are undifferentiated cells that divide and produce different types of cells. Ordinarily, cells that have differentiated into a specific cell type are post-mitotic—that is, they no longer divide. However, scientists have found a way to reprogram these mature cells so that they “de-differentiate” and return to an unspecialized, proliferative state. These cells are also pluripotent like embryonic stem cells—able to produce all cell types—and are therefore...
28.7K
Induced Pluripotent Stem Cells01:13

Induced Pluripotent Stem Cells

4.1K
4.1K
EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

3.5K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
3.5K
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

2.2K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Core Outcome Set for Localized Renal Cell Cancer (L-RCC-COS).

European urology focus·2026
Same author

Outcomes of Intermediate Risk Non-muscle-invasive Bladder Cancer Receiving Adjuvant Treatment: A Pooled Analysis of Four Randomized Controlled Trials.

European urology oncology·2026
Same author

The Imperial Prostate 9 - Approaches To Long-term Active Surveillance: Regular MRI scans versus standard of care (IP9-ATLAS) randomised controlled trial.

Contemporary clinical trials·2026
Same author

SET1B Drives Sustained HIF activity and Disease Progression in Clear Cell Renal Cell Carcinoma.

Cancer research·2026
Same author

Splicing factor TRA2B enhances synthesis of androgen receptor variant AR-V7 in prostate cancer cells.

The Journal of clinical investigation·2026
Same author

PARTIAL: study protocol for a clinical and cost-effectiveness of complex PARTIAL vs radical nephrectomy for clinically localised renal cell carcinoma randomised trial.

Trials·2026

Related Experiment Video

Updated: Apr 15, 2026

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells
08:52

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Published on: June 13, 2018

9.4K

Using induced pluripotent stem cells as a tool for modelling carcinogenesis.

Emma L Curry1, Mohammad Moad1, Craig N Robson1

  • 1Emma L Curry, Mohammad Moad, Craig N Robson, Rakesh Heer, Northern Institute for Cancer Research, Paul O'Gorman Building, Medical School, Newcastle University, Framlington Place, NE2 4HH Newcastle upon Tyne, United Kingdom.

World Journal of Stem Cells
|March 28, 2015
PubMed
Summary

Induced pluripotent stem cells (iPSCs) offer a novel approach to studying cancer development. By reprogramming somatic cells, iPSCs mimic cancer cell characteristics, aiding in disease modeling and understanding carcinogenesis.

Keywords:
CancerInduced pluripotent stem cellsModelReprogramming

More Related Videos

Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA
04:12

Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA

Published on: December 19, 2019

15.8K
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.6K

Related Experiment Videos

Last Updated: Apr 15, 2026

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells
08:52

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Published on: June 13, 2018

9.4K
Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA
04:12

Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA

Published on: December 19, 2019

15.8K
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.6K

Area of Science:

  • Oncology
  • Stem Cell Biology
  • Molecular Biology

Background:

  • Cancer remains a major global health challenge with high mortality rates.
  • Developing accurate human tissue models for cancer research is difficult.
  • Induced pluripotent stem cells (iPSCs) share properties with cancer cells, offering new research avenues.

Purpose of the Study:

  • To explore the similarities between cancer development and the iPSC reprogramming process.
  • To review the generation and application of iPSC models for various cancers.
  • To investigate how iPSCs can recapitulate cancer development and underlying mechanisms.

Main Methods:

  • Leveraging the Yamanaka factors (Oct4, Sox2, Klf4, c-Myc) for somatic cell reprogramming.
  • Generating iPSCs from human cancer cell lines and primary tumor samples.
  • Comparing the characteristics of iPSCs with those of cancer cells.

Main Results:

  • iPSCs exhibit key cancer-like features such as self-renewal, proliferation, stem cell marker expression, and altered metabolism.
  • Successful generation of iPSCs from diverse human cancer types has been achieved.
  • These iPSC models provide insights into cancer pathogenesis and development.

Conclusions:

  • The reprogramming process shares similarities with carcinogenesis, making iPSCs valuable tools for cancer research.
  • iPSC technology enables the creation of patient-specific cancer models for personalized medicine.
  • Further research using iPSC-derived cancer models can accelerate the discovery of novel cancer therapies.